BioAtla Inc (BCAB) Shares Up Despite Recent Market Volatility

BioAtla Inc (NASDAQ: BCAB) has seen a rise in its stock price by 3.55 in relation to its previous close of 3.52. However, the company has experienced a 21.10% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-19 that SAN DIEGO, March 19, 2024 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, March 26, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full-year ended December 31, 2023 and provide business highlights.

Is It Worth Investing in BioAtla Inc (NASDAQ: BCAB) Right Now?

Moreover, the 36-month beta value for BCAB is 1.05. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for BCAB is 38.53M and currently, short sellers hold a 13.31% of that float. On April 03, 2024, BCAB’s average trading volume was 471.37K shares.

BCAB’s Market Performance

BCAB stock saw an increase of 21.10% in the past week, with a monthly gain of 31.59% and a quarterly increase of 37.55%. The volatility ratio for the week is 16.38%, and the volatility levels for the last 30 days are 9.94% for BioAtla Inc (BCAB). The simple moving average for the last 20 days is 32.09% for BCAB stock, with a simple moving average of 56.53% for the last 200 days.

Analysts’ Opinion of BCAB

Many brokerage firms have already submitted their reports for BCAB stocks, with JMP Securities repeating the rating for BCAB by listing it as a “Mkt Outperform.” The predicted price for BCAB in the upcoming period, according to JMP Securities is $17 based on the research report published on September 15, 2022 of the previous year 2022.

Credit Suisse, on the other hand, stated in their research note that they expect to see BCAB reach a price target of $5, previously predicting the price at $35. The rating they have provided for BCAB stocks is “Neutral” according to the report published on May 05th, 2022.

H.C. Wainwright gave a rating of “Buy” to BCAB, setting the target price at $25 in the report published on March 21st of the previous year.

BCAB Trading at 42.81% from the 50-Day Moving Average

After a stumble in the market that brought BCAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -10.40% of loss for the given period.

Volatility was left at 9.94%, however, over the last 30 days, the volatility rate increased by 16.38%, as shares surge +31.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +82.00% upper at present.

During the last 5 trading sessions, BCAB rose by +20.93%, which changed the moving average for the period of 200-days by -2.67% in comparison to the 20-day moving average, which settled at $2.80. In addition, BioAtla Inc saw 48.17% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at BCAB starting from MCBRINN SYLVIA, who purchase 4,000 shares at the price of $2.33 back on Dec 26 ’23. After this action, MCBRINN SYLVIA now owns 15,125 shares of BioAtla Inc, valued at $9,320 using the latest closing price.

SHORT JAY M PHD, the Chief Executive Officer of BioAtla Inc, purchase 50,000 shares at $2.14 during a trade that took place back on Dec 20 ’23, which means that SHORT JAY M PHD is holding 1,439,283 shares at $106,910 based on the most recent closing price.

Stock Fundamentals for BCAB

The total capital return value is set at -1.42. Equity return is now at value -98.37, with -71.49 for asset returns.

Based on BioAtla Inc (BCAB), the company’s capital structure generated 0.03 points at debt to capital in total, while cash flow to debt ratio is standing at -42.28. The debt to equity ratio resting at 0.03. The interest coverage ratio of the stock is 88.22.

Currently, EBITDA for the company is -128.47 million with net debt to EBITDA at 0.85. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.11.

Conclusion

To wrap up, the performance of BioAtla Inc (BCAB) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts